Related Party Transactions	6 Months Ended
Jun. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions Astellas is an equity investor in the Company and is considered a related party. The Company recorded license and development revenue related to collaboration agreements with Astellas of $1.8 million for each of the three months ended June 30, 2023 and 2022, and $3.5 million and $29.6 million for the six months ended June 30, 2023 and 2022, respectively. The Company also recorded drug product revenue from Astellas of $14.3 million and $1.1 million for the three months ended June 30, 2023 and 2022, and $16.4 million and $8.7 million for the six months ended June 30, 2023 and 2022, respectively. See Note 2, Collaboration Agreements, License Agreement and Revenues, for details. The Company’s expense related to collaboration agreements with Astellas was immaterial for each of the three and six months ended June 30, 2023 and 2022. As of June 30, 2023 and December 31, 2022, accounts receivable from Astellas were $8.9 million and $1.5 million, respectively. As of June 30, 2023 and December 31, 2022, total deferred revenue from Astellas was $15.5 million and $40.3 million, respectively. As of June 30, 2023, the amounts due to Astellas, included in accounts payable, accrued and other current liabilities, and other long-term liabilities, totaled $30.4 million. As of December 31, 2022, the amount due to Astellas, included in accrued and other current liabilities, was $63.9 million. Falikang, an entity jointly owned by FibroGen Beijing and AstraZeneca is an unconsolidated VIE accounted for as an equity method investment, and considered as a related party to the Company. FibroGen Beijing owns 51.1% of Falikang’s equity. See Note 4, Equity method investment - Variable Interest Entity, for details. The net product revenue from Falikang was $20.5 million and $19.7 million for the three months ended June 30, 2023 and 2022, and $41.9 million and $36.0 million for the six months ended June 30, 2023 and 2022, respectively. See the Product Revenue, Net section in Note 2, Collaboration Agreements, License Agreement and Revenues, for details. The investment income in Falikang was $0.6 million for each of the three months ended June 30, 2023 and 2022, and $1.3 million and $0.9 million for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023 and December 31, 2022, the Company’s equity method investment in Falikang was $6.1 million and $5.1 million, respectively. See Note 4, Equity method investment - Variable Interest Entity, for details. The other income from Falikang was immaterial for each of the three and six months ended June 30, 2023 and 2022. As of June 30, 2023 and December 31, 2022, accounts receivable, net, from Falikang, were $11.0 million and $10.5 million, respectively.

Related Party Transactions

6 Months Ended

Jun. 30, 2023

11. Related Party Transactions

Astellas is an equity investor in the Company and is considered a related party. The Company recorded license and development revenue related to collaboration agreements with Astellas of $1.8 million for each of the three months ended June 30, 2023 and 2022, and $3.5 million and $29.6 million for the six months ended June 30, 2023 and 2022, respectively. The Company also recorded drug product revenue from Astellas of $14.3 million and $1.1 million for the three months ended June 30, 2023 and 2022, and $16.4 million and $8.7 million for the six months ended June 30, 2023 and 2022, respectively. See Note 2, Collaboration Agreements, License Agreement and Revenues, for details.

The Company’s expense related to collaboration agreements with Astellas was immaterial for each of the three and six months ended June 30, 2023 and 2022.

As of June 30, 2023 and December 31, 2022, accounts receivable from Astellas were $8.9 million and $1.5 million, respectively.

As of June 30, 2023 and December 31, 2022, total deferred revenue from Astellas was $15.5 million and $40.3 million, respectively.

As of June 30, 2023, the amounts due to Astellas, included in accounts payable, accrued and other current liabilities, and other long-term liabilities, totaled $30.4 million. As of December 31, 2022, the amount due to Astellas, included in accrued and other current liabilities, was $63.9 million.

Falikang, an entity jointly owned by FibroGen Beijing and AstraZeneca is an unconsolidated VIE accounted for as an equity method investment, and considered as a related party to the Company. FibroGen Beijing owns 51.1% of Falikang’s equity. See Note 4, Equity method investment - Variable Interest Entity, for details.

The net product revenue from Falikang was $20.5 million and $19.7 million for the three months ended June 30, 2023 and 2022, and $41.9 million and $36.0 million for the six months ended June 30, 2023 and 2022, respectively. See the Product Revenue, Net section in Note 2, Collaboration Agreements, License Agreement and Revenues, for details.

The investment income in Falikang was $0.6 million for each of the three months ended June 30, 2023 and 2022, and $1.3 million and $0.9 million for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023 and December 31, 2022, the Company’s equity method investment in Falikang was $6.1 million and $5.1 million, respectively. See Note 4, Equity method investment - Variable Interest Entity, for details. The other income from Falikang was immaterial for each of the three and six months ended June 30, 2023 and 2022.

As of June 30, 2023 and December 31, 2022, accounts receivable, net, from Falikang, were $11.0 million and $10.5 million, respectively.